Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
Abstract The development of an effective oral therapeutics is an immediate need for the control and elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of 2-hydroxypropyl-β-cyclodextrin (HPCD) modified solid lipid nanoparticles (SLNs) based oral combinational ca...
Guardado en:
Autores principales: | Shabi Parvez, Ganesh Yadagiri, Mallikarjuna Rao Gedda, Aakriti Singh, Om Prakash Singh, Anurag Verma, Shyam Sundar, Shyam Lal Mudavath |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/87cd75c07e3141f596bdb338820aa6fb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Risk factors for visceral leishmaniasis and asymptomatic Leishmania donovani infection in India and Nepal.
por: Albert Picado, et al.
Publicado: (2014) -
Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Danfeng Ren, et al.
Publicado: (2021) -
Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis.
por: Pramod K Kushawaha, et al.
Publicado: (2012) -
Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
por: Tiget Ayelgn Mengstie, et al.
Publicado: (2021) -
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs.
por: Shri Prakash Singh, et al.
Publicado: (2011)